Xtandi Exhibits Long-term Survival Benefits in ARCHES and ENZAMET Trials

Updated long-term data from the ARCHES and ENZAMET studies, released by Pfizer and Astellas, highlight the durable overall survival benefits of Xtandi (enzalutamide) in treating mCSPC. After an extended follow-up period of eight years, ARCHES data revealed a median overall survival of 8.0 years for patients treated with Xtandi versus 5.8 years for standard care (HR 0.73). Similarly, the ENZAMET study, with a median follow-up of 98 months, reinforced these findings, demonstrating sustained survival advantages for Xtandi when used in conjunction with testosterone suppression therapy, with or without chemotherapy. These robust, long-term results solidify Xtandi’s role as a reliable, effective frontline therapeutic choice in mCSPC.

Citation: Pfizer Press Release, June 2025. Available at: https://www.pfizer.com/news/press-release/press-release-detail/astellas-and-pfizers-xtanditm-enzalutamide-shows-long-term

Implication: Sustained survival benefits further establish Xtandi’s credibility as a durable and effective frontline mCSPC treatment.